Literature DB >> 23318602

Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.

Denis Ouzan, Guillaume Pénaranda, Hélène Joly, Philippe Halfon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23318602     DOI： 10.1016/j.jhep.2012.12.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

1.  Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial.

Authors:  Zaigham Abbas; Mohammad Sadik Memon; Muhammad Amir Umer; Minaam Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2016-05-18

2.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

Review 3.  The role of HBsAg levels in the current management of chronic HBV infection.

Authors:  Christoph Höner Zu Siederdissen; Markus Cornberg
Journal:  Ann Gastroenterol       Date:  2014
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.